Resumo

ROMAN, Elena et al. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (Madr.) [online]. 2017, vol.37, n.5, pp.478-491. ISSN 1989-2284.  https://dx.doi.org/10.1016/j.nefro.2017.01.006.

Understanding the role of the complement system in the pathogenesis of atypical haemolytic uraemic syndrome and other thrombotic microangiopathies (TMA) has led to the use of anti-complement therapy with eculizumab in these diseases, in addition to its original use in patients with paroxysmal nocturnal haemoglobinuria andatypical haemolytic uraemic syndrome. Scientific evidence shows that both primary and secondary TMAs with underlying complement activation are closely related. For this reasons, control over the complement system is a therapeutic target. There are 2scenarios in which eculizumab is used in patients with TMA: primary or secondary TMA that is difficult to differentiate (including incomplete clinical presentations) and complement-mediated damage in various processes in which eculizumab proves to be efficacious. This review summarises the evidence on the role of the complement activation in the pathophysiology of secondary TMAs and the efficacy of anti-complement therapy in TMAs secondary to pregnancy, drugs, transplant, humoral rejection, systemic diseases and glomerulonephritis. Although experience is scarce, a good response to eculizumab has been reported in patients with severe secondary TMAs refractory to conventional treatment. Thus, the role of the anti-complement therapy as a new treatment option in these patients should be investigated.

Palavras-chave : Secondary thrombotic microangiopathies; Complement activation; Eculizumab.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )